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Abstract. After the partial denervation or paralysis of 
a  muscle, the remaining motor axon terminals may 
sprout fine, neuritic processes (terminal sprouts) 
which escape the endplate region of the neuromuscu- 
lar junction.  We previously identified a  muscle-de- 
rived, protein antigen of 56,000 daltons (56 kD) 
which plays a  necessary role in terminal sprouting. A 
panel of monoclonal antibodies have been produced 
against the 56-kD antigen, some of which also par- 
tially suppress motor axon terminal sprouting. These 
monoclonal antibodies define at least two different 
epitopes upon the surface of the antigen, one of which 
is necessary for it to effect its biological role in vivo. 
I 
N response to partial denervation or paralysis, the motor 
axon  terminals  remaining  within  a  muscle  frequently 
sprout fine neuritic processes that escape the muscle fiber 
endplate (7). Such sprouts are called either terminal or ultra- 
terminal sprouts, depending on the author. Terminal sprouts 
can reinnervate denervated muscle fiber endplates or induce 
de novo neuromuscular synapses. Muscle is believed to pro- 
vide a  signal which  is important for induction  of terminal 
sprouting, but the molecular nature of  the signal is not known. 
Whether released by the muscle (if soluble), exposed on the 
muscle surface, or inserted in the basal lamina (if substrate 
bound),  the  signal  should  be  induced  by  denervation  or 
muscle paralysis. Muscle activity per se appears to control the 
expression of the  signal for terminal sprouting,  as terminal 
sprouting  is  suppressed  by  direct  electrical  stimulation  of 
denervated or paralyzed muscle (4, 5). After partial denerva- 
tion, a  second type of sprouting is also observed in muscle. 
The remaining motor axons will  also sprout new processes 
from nodes of Ranvier, although nodal sprouting is not sup- 
pressed by direct electrical stimulation of  muscle (5, 23). Thus, 
the molecular requirements for nodal sprouting must differ 
in part from those responsible for terminal sprouting. In man, 
it is nodal sprouting that is primarily responsible for reinner- 
vation of muscle in disease or after trauma to the nerve (11, 
41). 
The final test of a  candidate  "terminal sprouting factor" 
must be that  the  agent alone is sufficient to induce  motor 
axon terminal sprouting in vivo. We do not know if such an 
agent should  also play a  role in  nodal  sprouting.  We have 
pursued an immunological approach in an attempt to identify 
factors produced by denervated or inactive muscle that might 
be  necessary for motor axon  terminal  sprouting.  We have 
prepared a  series  of rabbit antisera against  components of 
denervated muscle-conditioned medium (16).  By fractiona- 
tion  of the  conditioned  medium (CM), l  and  by producing 
successive  rounds  of antisera,  we  succeeded  in  producing 
antisera of limited specificity that suppressed axon terminal 
sprouting  at  the  neuromuscular  junction.  The  antisera 
pointed to a protein of 56,000 daltons (56 kD) as the effective 
antigen  in the immunizations. An  independent line of evi- 
dence which further implicated the 56-kD antigen in terminal 
sprouting was provided by work with clinical material. Sera 
from several neurological patients with a degenerative disease 
of the  motor neuron,  amyotrophic lateral  sclerosis  (ALS), 
were  shown  to  suppress terminal  sprouting in  the  in  vivo 
assay  and  to  contain  antibodies  reactive  with  the  56-kD 
antigen (17). Since none of the rabbit antisera were monospe- 
cific,  it became necessary to produce monoclonal antibodies 
against the 56-kD antigen in order to demonstrate that it was 
indeed the effective antigen in the immunization. 
We now describe the generation of a panel of monoclonal 
antibodies (mAb's) against the 56-kD antigen and show that 
a subset of the mAb suppresses motor axon terminal sprout- 
ing.  The  results  obtained with  the  immunological reagents 
indicate  that  the  56-kD  antigen  plays  a  necessary  role  in 
motor axon terminal sprouting. 
Materials and Methods 
Preparation of  lmmunogen 
Adult Sprague-Dawley  rat  hemidiaphragms were  denervated by cutting the 
phrenic nerve intrathoracically and cultured as described  previously (16). The 
1.  Abbreviations  used in  this paper." ALS, amyotrophic lateral  sclerosis;  AS, 
ammonium sulfate; CM, conditioned medum; ELISA, enzyme-linked immu- 
nosorbent assay; mAb, monoclonal antibody; N-CAM, neural cell  adhesion 
molecule; NGF, nerve growth factor;  RIA, radioimmune assay. 
© The Rockefeller University Press, 0021-9525/86/06/2264/09 $1.00 
The Journal of Cell Biology, Volume 102, June 1986 2264-2272  2264 CM  was stored  frozen at -20"C until  used.  Before precipitation  with  solid 
ammonium sulfate (AS), the thawed CM was buffered at pH 6.5 by addition 
of 1:10 vol of 0.5  M  NaPi,  50 uM Na EDTA,  5 mM Na EGTA,  100 #M 
leupeptin,  and 0.1  M phenylmethylsulfonyl  fluoride, and centrifuged for 30 
rain at  13,000 rpm in a Sorvall GSA rotor at 4"C. The CM was precipitated 
initially at 4"C by addition  of AS to 190 g/liter initial volume. After the first 
precipitate was collected by centrifugation,  additional  AS was added to bring 
the solution to 380 g of AS per liter of initial volume. The 190-380-g AS/liter 
precipitate  was  collected  by  centrifugation  and  then  dialyzed  against  two 
changes of 4 liters 20 mM NaPi (pH 7.5). The dialyzate was passed over a 1.6 
x  15 cm column of DE52 (Whatman Inc., Clifton, N  J) and eluted sequentially 
with  steps  of increasing  NaCI  concentration  in  20  mM  NaPi  (oH 7.5) as 
indicated in Fig. 1. 
Immunization and Hybridoma Fusion 
Male,  150-200-g Lewis rats were immunized at  14-d intervals with  ~50 #g 
protein  of the 0.25 M  NaCI DE52  fraction.  The antigen  was emulsified in 
Freund's complete  adjuvant  for the  first two injections  and  in incomplete 
adjuvant for the third immunization.  The emulsion was injected intradermally 
at multiple  sites across the animal's back. The serum antibody  response was 
assayed 8 wk after the initial immunization by immunoblotting.  Three more 
injections of antigen in phosphate-buffered  saline (PBS) were delivered at l-d 
intervals immediately before killing, at which time the mechanically dispersed 
spleen cells were ftactionated by centrifugation onto a FicolI-Hypaque cushion 
of 1.094 g/ml density, and then fused at a ratio  of 10:l with  mouse SP2/0 
mouse myeloma cells using polyethylene glycol (12). 1 d after fusion, the cells 
were dispersed into fourteen 96-well plates. The microcultures were subjected 
to selection with hypoxanthine-aminopterin-thymidine  and then were screened 
by an enzyme-linked immunosorbent  assay (ELISA) as described below. 
Some hybridoma lines were subeloned in soft agarose on a feeder layer of 
gamma-irradiated  spleen cells. Ascites fluid was prepared  in nude mice (nu/ 
nu) primed with 0.1 ml pristane injected intraperitoneally  l0 d before innocu- 
lation with 2--4 x  106 hybridoma cells. Ochterlony analysis of  rat immunoglob- 
ulin subclass was performed with Miles subclass-specific anti-rat immunoglob- 
ulin antisera. 
B109.9, an IgM, was purified from ascites fluid by precipitation with 280 g/ 
liter of AS, eluted from DE52 with a gradient of  0-0.3 M NaCI in 20 mM NaPi 
(pH 7.5); gel  filtration  over Sepharose  CL 4B (Pharmacia  Fine  Chemicals, 
Piseataway, NJ) followed. B86.3, an lgG2a, was purified from ascites fluid by 
precipitation with 280 g per liter of AS followed by chromatography over DE52 
in  5 mM  NaPi  (pH 8.0). Purity  of both preparations  was verified by SDS 
PAGE. 
Immunoblotting 
SDS PAGE and immunoblotting was performed as described previously (16). 
Hybridoma supernatants were buffered by addition of 1:10 vol of 0.5 M NaPi 
(pH 7.5) and nitrocellulose strips were incubated with 5 ml of  solution overnight 
at 4"C. Ascites fluids were used at a dilution  of 1:400 in 3%  bovine  serum 
albumin (BSA), PBS, 0.05% Twcen 20.  Bound  rat immunnglobulin was de- 
tected with rabbit anti-rat IgG (Miles Laboratories, Inc., Elkhart, IN) used at a 
dilution  of 1:2,000 which  was then reacted  with  ~25I-labeled protein  A (l& 
cpm/#g; 1.5 x  l0  s cpm/ml diluent). Autoradiography against XAR5 film was 
performed  overnight  at  -70"C.  Unreacted  sites  on the  nitrocellulose  were 
blocked with 3% gelatin in PBS and all subsequent buffer solutions contained 
0.05% Twecn 20. 
ELISA 
Flexible roland-bottom  micro ELISA plates (Dynatech Laboratories,  Inc., Al- 
exandria,  VA) were coated overnight  at 4"C with 50 #l of the 0.25 M NaCI 
DE52 fraction diluted to 8 ug/ml in 150 mM sodium bicarbonate buffer (pH 
9.6). The wells were blocked with 0.1% BSA in the bicarbonate buffer for 1 h 
at 37*(7, and then were reacted with 75 ~1 of hybridoma culture supernatant 
for 2 h at 37"C in an atmosphere  of 5% CO2. Bound  immunoglobulin  was 
detected with a biotinylated anti-rat IgG, avidin-horseradish  peroxidase system 
(Vectastain) developed with o-phenylene diamine and hydrogen peroxide. 
Two-Site Radioimmune Assay (RIA) 
Microtiter  wells were coated  with either  B130.6 ascites fluid at a dilution  of 
1:1,000 or with B216 aseites fluid at  1:5,000 in  150 mM bicarbonate  buffer 
(pH 9.6) for 2 h at 37"C. After blocking unreacted  plastic with  1% gelatin in 
PBS for 1 h at 37"C, the wells were incubated with serial dilutions of  the antigen 
in 3% BSA, 0.05% Twcen 20 in PBS for 2 h at 37"C (as indicated in Fig. 7). 
B130.6  and  B216 mAb's were  internally  labeled with  [3SS]methionine by 
incubating the hybridoma cells (10  s cells per microtiter culture well) in methi- 
onine-frce RPMI  1640 containing  400 #Ci/ml [3SS]methionine  (1.3 Ci/mmol; 
Amersham Corp.,  Arlington  Heights,  IL;  SJ.204) for 4  h  at  37°C in  an 
atmosphere of 8% CO2. Incorporation  of label into the mAb was evaluated by 
SDS PAGE  (see Fig. 7).  [a~S]-labeled mAb was partially  purified  from the 
culture  supernatant by gel  filtration  over AcA44 (LKB  Instruments, Inc., 
Gaithersburg, MD; column dimensions  1.1 x  18 cm) in 0.3% BSA, PBS, 0.05% 
Tween 20. In the two-site RIA, 10,000 clam of  trichloroacetic acid-precipitable 
counts were added per well and incubated  2 h at 37"C. Atter rinsing with PBS 
containing 0.05% Twcen 20, bound [3sS]-Iabeled mAb was eluted with  100 ul 
of 0.1  N NaOH, the solution was acidified with  100 ill of 1 N HCI, and then 
counted  in  5  ml  of Aquasol  (New  England  Nuclear,  Boston,  MA)  liquid 
scintiUant. 
Gluteus Muscle Assay of Uitraterminal Sprouting 
Female ICR mice (20-24  g) were innoculated  subcutaneously  over the right 
gluteus muscle with -250 lag of botulinum toxin Type A (Sigma Chemical Co., 
St. Louis, MO) in 5 t~l of 70 mM NaPi,  0.2% gelatin buffer (pH 6.5). The 
percentage of gluteal motor axon terminals that develop sprouts scales linearly 
with toxin dose. The dose selected produced no mortality. On each of the next 
6 d after injection  of toxin,  mice were innoculated  subcutaneously  over the 
surface of the paralyzed gluteus muscle with 0.1  ml of heat-inactivated ascites 
fluid (56°C, 30 rain) as in Table I, with ascites fluid diluted  in PBS (10 mM 
NaPi, 0.9% NaCI buffer, pH 7.5) to a final injection volume of  0.1 ml (see Fig. 
8), or with purified mAb diluted in PBS (Table II). Groups of eight mice were 
exposed to each treatment.  Controls were groups of mice that were innoculated 
with just toxin or that received toxin  followed by a series of daily injections 
with PBS. 7 d after injection with toxin, the mice were killed, the gluteus muscle 
was excised, stained with zinc iodide-osmium  tetroxide for 3 h in the dark at 
room temperature  (23), and then prepared for examination  as a whole mount 
by clearing  in  xylene and  mounting in  Permount.  The terminals  were left 
undisturbed  by the dissection. Slides were coded before microscopical exami- 
nation.  The percentage of sprouting terminals within the zone of innervation 
of the superior gluteal nerve was used as the index of terminal  sprouting. The 
length of  sproutS or other indices of  sprouting  were not quantitated.  On average, 
100 terminals were scored per muscle. Data axe expressed as the mean 4- SEM 
for the number of animals (eight mice). 
Results 
Partial Purification of the 56-kD Antigen by 
Anion-Exchange Chromatography 
We had  available a  rabbit antiserum,  DI0, that was raised 
against  a  preparation  of the  56-kD  antigen  that  had  been 
partially purified by SDS PAGE. D10 suppresses motor axon 
terminal sprouting as described previously (16). Immunoblot- 
ting with DI0 was used to follow the 56-kD antigen through 
Table L Immunoglobufin Subclass and Suppression of 
Motor Axon Terminal Sprouting by Anti-56-kD 
Hybridoma Ascites Fluid 
Percent terminals  Percent 
mAb  Class*  sprouting  inhibition* 
Toxin 1  70 _  8  0 4, 8 
Toxin 2  74 4, 4  0 4. 8 
PBS  73 4. 5  0 4. 7 
B5  IgG2a  51  4- 6  29 4, 8 
B70.10  IgM  57 4, 6  20 4. 8 
B86.3  IgG2a  58 4- 8  20 4,  11 
B109.9  IgM  36 4- 8  50 4,  11 
B130.6  IgG2b  35 +  8  51  4.  11 
B135  IgM  36 4. 5  50 4. 7 
B216  IgG2b  ~  0  +  8 
* Determined  by Ochterlony double-diffusion assay with rat immunoglobulin 
subclass specific antisera. 
*  Calculated from the average percent terminals sprouting for the toxin 1 and 
toxin 2 groups. 
! B216 ascites fluid was tested in the experimental series of Table II. 
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the  56-kD  antigen by anion-ex- 
change chromatography. Immuno- 
blot .analysis  of  the  denervated 
diaphragm--conditioned  medium 
(CM),  fractions from the ammo- 
nium  sulfate  (AS)  precipitation, 
and  fractions  from  the  DE52 
anion-exchange  chromatography 
(DE52).  50  t~g total protein was 
analyzed in each lane. The samples 
were fractionated by SDS PAGE, 
transferred to  nitrocellulose,  and 
the  transfers  were  reacted  with 
DI0  (1:50  dilution) followed  by 
t25I-labeled protein  A  to  detect 
bound rabbit IgG. The 56-kD an- 
tigen (arrow)  was detected in the 
denervated  diaphragm--condi- 
tioned medium,  the  190-380  g/ 
liter and 380 g/liter AS fractions, 
and in the 0.25 M NaCI and 0.35 
M NaC1 eluates of the DE52 col- 
umn. The antigen remains a minor 
constituent of the 0.25  M  NaC1 
DE52  fraction as shown  in Fig. 5 
(left). 
a  simple fractionation of the denervated diaphragm-condi- 
tioned medium by fractional precipitation with AS and elu- 
tion  from  DEAE-cellulose  with  steps  of  increasing  ionic 
strength. The 56-kD antigen precipitated with a  cut of 190- 
380 g of AS per liter, was retained by DE52, and eluted with 
a  step from 0.15-0.25  M  NaCl (Fig.  1).  The 56-kD antigen 
remains a minor constituent of the immunogen (as illustrated 
in Fig. 5, left). Some 56-kD antigen remained soluble in 380 
g of AS per liter, so in later experiments the amount  of AS 
added was increased to 560 g/liter. 
Congenic Immunization  Produces Antisera of 
Limited Specificity 
We immunized three adult male Lewis rats with the 0.25  M 
NaC1 DE52  fraction obtained from Sprague-Dawley rat de- 
nervated diaphragm-conditioned medium.  If the Lewis rats 
responded to the congenic antigen, we felt that the genetic 
relatedness of the two  strains would limit the animals' im- 
mune response to serum proteins that contaminated the im- 
munogen. The two rats that responded to the 56-kD antigen 
produced  highly  specific antisera  (designated  R2  and  R3) 
despite the  relative impurity of the  antigen  in  the  0.25  M 
NaC1 DE52  fraction (Fig. 2).  The spleen from R2 was used 
in the first fusion, and that from R3 in the second fusion. 
Figure 2. Congenic immunization elicits  antisera of limited specificity 
as assayed by immunoblotting. Three rats were immunized with the 
0.25  M  NaCI  DE52  eluate.  A sample of the immunogen (100  #g 
protein) was fractionated by SDS PAGE and transferred to nitrocel- 
lulose. The replicate transfers  were reacted with sera from the im- 
munized rats (R1-R3) as indicated at a dilution of either  1:50 or 
1:100. Bound rat Ig was detected with I- 125-labeled goat anti-rat IgG 
(Cappel Laboratories, Cochranville, PA). The sera obtained from R2 
and R3 reacted highly specifically with an antigen of 56 kD (arrow) 
at a dilution of 1:100. A representative protein stain of the 0.25  M 
NaCI DE52 immunogen is illustrated in Fig. 5 (left). 
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an antigen of 56 kD (Fig. 2). When the photo was taken, R1 weighed 440 g while R3 weighed 273 g. R3 was markedly thinner than R1 along 
its flanks and throughout its hind legs. R3's tail noticeably kinked, and discoloration by fecal material of both the fur on top of its head and its 
tail indicated impaired grooming. R3 was noticeably weak in forepaw grip (tested by pulling the rat over a wire grid) and easily exhausted. In 
the center photo, R3 has been pulled across a flat surface by its tail and then released. It was slow to resume a normal body posture with both 
hind and fore legs tucked beneath its body. In c, histology of the gastrocnemius muscle from the affected hind limb is normal. The muscle was 
frozen sectioned at  15 um and stained with hematoxylin  and eosin. Had muscle denervation  been present,  atrophic  muscle fibers of small 
diameter should have been visible. 
By 4-6 mo into the immunization, both R2 and R3 showed 
loss of weight, apparent muscle wasting, and motor deficits, 
while R l, a rat that developed a weak response to the 56-kD 
antigen,  remained  healthy.  The forepaw grip of R2 and R3 
seemed  weak  compared  to  R1  or  unimmunized  rats,  and 
when their back legs were extended, R2 and R3 showed little 
tendency to resume a  normal posture (Fig.  3).  Superficially, 
the  appearance  of the  rats  corresponded to  what  might  be 
expected in an animal  model of ALS, however, no signs of 
muscle denervation were noted in the gastrocnemius muscle 
from  one of the  affected hindlimbs  of R3,  nor was loss of 
ventral  horn  neurons  noted  in  the  lumbar  spinal  cord  or 
medulla.  (The  histology  was  performed  by  K.  Steffanson, 
M.D., Department of Neurology and Pathology, The Univer- 
sity of Chicago.) 
Fusion and Screening of  Hybridomas for mAB against 
the 56-kD Antigen 
Blast cells from an immunized rat's spleen were collected by 
centrifugation onto a cushion of Ficoll-Hypaque (1.094 g/ml) 
and  were  then  fused  with  mouse  SP2/0  myeloma cells  by 
using polyethylene glycol. After selection  of the  hybrids  in 
hypoxanthine-aminopterin-thymidine, we performed a  two- 
step screen of the antibody secreted by the hybridoma lines. 
Since the animals' response to irrelevant antigens present in 
the immunogen was limited, we initially screened the hybrid- 
oma supernatants  for binding in an ELISA with the 0.25 M 
NaC1  DE52  fraction.  As  we  did  not  have  purified  56-kD 
antigen available, we could not use the ELISA to demonstrate 
specificity. To select specific, anti-56-kD mAb, ELISA-posi- 
tive hybridomas were grown up to flasks and then the super- 
natants were rescreened by immunoblotting. 
In two fusions of spleen  cells obtained  from  R2 and  R3 
with mouse SP2/0 myeloma cells, we generated 1118 hybrid- 
oma lines that were screened by ELISA.  188  of them were 
positive  in  the  ELISA.  Of these,  109  hybridomas were  re- 
screened by immunoblotting (79 of 109  lines from the first 
fusion were discarded) and seven hybridomas were obtained 
that were positive by immunoblotting for anti-56-kD mAb. 
All seven were obtained in the second fusion with spleen cells 
from R3. 
To establish the ELISA, we compared binding of antibody 
in immune serum from R2 and R3 with preimmune sera to 
microtiter  wells  coated  with  varying concentrations  of the 
0.25  M  NaC1 DE52 fraction. As the wells were coated with 
increasing amounts of antigen (Fig. 4, top), both R2 and R3 
showed greater binding than preimmune serum. A concentra- 
tion of 8  #g protein/ml  of the  immunogen was chosen for 
coating the microtiter wells for the ELISA screen. 
In the screen, wells varied from twice background to satu- 
ration of the ELISA. After anti-56-kD mAb's were selected 
by immunoblotting, we sought to validate retrospectively the 
initial  ELISA screen.  Serial dilutions  of the anti-56-kD hy- 
bridoma supernatants were reacted with wells coated with 8 
~g protein per milliliter of the 0.25  M  NaCl DE52 fraction. 
All anti-56-kD mAb tested  reacted positively in the ELISA 
(Fig. 4b). 
Most of the  hybridoma supernatants  failed  to react with 
any antigen on the nitrocellulose transfers.  Immunoblotting 
with  the  panel  of anti-56-kD  mAb is  illustrated  in  Fig.  5. 
Each reacts with a band of 56 kD. 
Four  of the  seven  hybridomas  were  subcloned  in  soft- 
agarose (B86.3,  B70.10,  B 109.9,  and  B 130.6).  Ascites fluid 
was prepared from each of the cell lines by passage in nude 
mice.  The subclass  of antibody being secreted by each line 
was characterized by immunodiffusion in Ochterlony plates 
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Figure 4. ELISA with rat sera and anti-56-kD hybridoma culture 
supernatants. In the top panel, the microtiter wells were coated with 
serially decreasing concentrations of the 0.25 M NaCI DE52 eluate 
and then reacted with the immune sera obtained from R2 and R3 
and with the preimmune serum from R2 (preR2). Both R2 and R3 
reacted more strongly than  the preimmune serum  in the ELISA. 
Hybridoma culture supernatants were  initially screened  with  the 
ELISA and then rescreened  by immunoblotting as in Fig. 5. Of 82 
hybridoma supernatants which  were positive in the ELISA, seven 
were found to contain immunoglobulin that reacted with an antigen 
of 56 kD on nitrocellulose transfers of the 0.25 M NaC1 DE52 eluate 
as fractionated by SDS PAGE (Fig. 5). In the bottom panel, serial 
against rat  immunoglobulin  subclass specific antisera  pur- 
chased from Miles Laboratories, Inc. (Table I). 
Suppression  of  Motor Axon Terminal Sprouting at the 
Neuromuscular Junction by the Anti-56-kD mAb 
The gluteus is a thin sheet of muscle in the mouse and only 
3-5  muscle  fibers  thick  through  its  midsection  (22).  The 
muscle sheet  is innervated  by two  branches  of the gluteal 
nerve  which  enter the  muscle at  its posterior and  anterior 
margins and join across its center. The number of terminals 
that developed ultraterminal sprouts was quantitated within 
the thin, central region of the muscle (16). Botulinum toxin 
paralyzes a  muscle  by  preventing  neurotransmitter  release 
(acetylcholine)  from  the  motor  axon  nerve  terminal.  We 
injected the toxin subcutaneously across the surface of the 
muscle. The dose chosen was nonlethal and caused 74 __. 8% 
of  the gluteal nerve terminals to develop ultraterminal sprouts. 
Histological  examination  of  the  muscle  was  conducted 
"blind," at least 100 terminals per muscle were scored, and 
generally 3-4 treatment groups of eight mice each were coded 
randomly and read as a group before breaking the code. The 
zinc iodide-osmium tetroxide stain clearly demonstrates the 
unmyelinated portion of the preterminal axon and details of 
the  nerve  terminal  morphology.  Any  fine  process growing 
from the normally smooth contour of the nerve terminal that 
"escaped"  the  endplate  was  classified  as  an  ultraterminal 
sprout  (Fig.  6).  Indices  of terminal  remodeling within  the 
endplate region such as the size of the endplate or the number 
of branches made by the claw-like terminal within the end- 
plate region were not quantitated (see reference 30). The latter 
are  suppressed  by  anti-acetylcholine receptor  antibody  in 
myasthenic sera or by alpha-bungarotoxin, but  myasthenic 
sera do not suppress botulinum toxin-induced ultraterminal 
sprouting in the mouse. 
A  pair of mAb's, B130.6  and B216,  exemplify the results 
obtained with the in vivo assay. B130.6  suppresses terminal 
sprouting by 50%, whereas B216  has no effect in the assay. 
Both of the mAb's are of the same subclass, IgG2b, as shown 
by Ochterlony assay and by the molecular mass of their heavy 
chains (55-kD), which is also characteristic of rat IgG2b (32). 
The antigen-binding domains of the two mAb's are distinct 
as their  light chains differ substantially in  molecular mass 
(Fig.  7).  Since the  two  mAb's share the  same  heavy chain 
effector domains, the difference in their ability to  suppress 
terminal  sprouting  must  reside  in  the  antigen-binding do- 
main. Either each mAb recognizes a different epitope on the 
56-kD antigen, in which case B130.6  must define a  domain 
of the  56-kD  protein  which  is  functionally  important  for 
terminal sprouting, or both recognize the same epitope but 
the affinity of B216 for that epitope is much less than that of 
B 130.6.  To address this question, we determined if the two 
mAb's could form  a  sandwich with the 56-kD antigen in a 
two-site  RIA.  To  perform  the  RIA,  mAb's  from  the  two 
dilutions of the anti-56-kD hybridoma culture supernatants were 
reacted with microtiter wells coated with a constant amount of the 
0.25  M  NaCI  DE52  eluate at  8  #g protein/ml. All showed  good 
binding in the ELISA. Bound rat Ig was detected with biotinylated 
goat anti-rat IgG followed  by strepavidin: biotinylated horseradish 
peroxidase conjugate.  The wells were developed with o-phenylenedi- 
amine and optical density at 450 nm (0D45o) was determined with a 
Titertek dual wavelength ELISA plate reader. 
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kD mAb. The 0.25 M NaCI DE52 
eluate  was  fractionated  by  SDS 
PAGE,  transferred  to  nitrocellu- 
lose, and then transfers of individ- 
ual lanes were reacted with differ- 
ent  immunochemical  reagents  as 
indicated. The results of three sep- 
arate  experiments  are  illustrated. 
(Left)  Replicate  transfers  have 
been  stained  for  protein  with 
Amido black or reacted with D I0. 
DI0 identifies ar~ antigen of 56 kD 
(arrow).  (Center) Replicate trans- 
fers have been  incubated without 
monoclonal  antibody  (no  mAb), 
with  ascites  fluid  prepared  from 
the  SP2/0  myeloma  fusion  part- 
ner, or with MCB-1, an anti-NGF 
rat  IgG2b  mAb  (42),  at  10  ~g 
IgG2b per milliliter as controls, or 
with B109.9 or B216 ascites fluid 
(1:400).  B109.9 and B216 ident!fy 
an  antigen  of  56  kD  (arrow). 
(Right)  Replicate  transfers  have 
been  reacted  with  ascites  fluids 
prepared from the panel of mAb. 
All react with an antigen of 56 kD 
(arrow).  Reactivity with an antigen 
of 67 kD is also observed, as well 
as with some low molecular mass 
material. The antigen of 67 kD is thought to be rat serum albumin.  Because the preparation  of the 56-kD antigen was not highly purified, 
serum protein  which was washed out of the cultured hemidiaphragm provides the bulk of contaminating protein.  Rat IgG2b was variably 
present in the 0.25  M  NaC1 DE52 fraction and proved to be especially troublesome as its heavy chain has a relative mobility on SDS PAGE 
(55 kD) which is similar to "that of the 56-kD antigen. 
Figure 6. Histology of zinc iodide- 
osmium  tetroxide-stained  motor 
axon terminals in normal muscle 
(normal) or  in  muscle  paralyzed 
with botulinum toxin and exposed 
to  B216  ascites  fluid  (B216) or 
B130.6  ascites fluid (B130.6). Ter- 
minal  axonal  sprouting  was  in- 
duced  by  botulinum  toxin;  the 
mice were then injected with 0.1 
ml of ascites fluid subcutaneously 
over  the  botulinum-intoxicated 
gluteus muscle on each of the next 
6  d,  and  the  muscle  was excised 
and  stained  with  zinc  iodide-os- 
mium tetroxide 7 d after injection 
with toxin. B 130.6 maximally sup- 
pressed  terminal  sprouting  by 
~50% while terminal sprouting was unaffected by exposure to B216.  With the exception that fewer terminals had sprouts in muscles treated 
with B130.6 as compared to B216, no other histological differences were noted. No sprouts are seen in the normal muscle. Terminals with 
sprouts escaping the endplate region in the botulinum-treated muscles are indicated by the arrows. 
hybridoma lines were internally labeled with [35S]methionine. 
Plastic microtiter wells were coated with unlabeled B 130.6 or 
B216  in  ascites  fluid,  incubated  with  serial  dilutions  of the 
immunogen  which  contained  the  56-kD  antigen,  and  then 
were incubated with one of the internally labeled mAb's. The 
results obtained were consistent with recognition by the mAb 
of two different epitopes on the 56-kD antigen,  as illustrated 
in Fig. 7. 
Are There Two Signals for Terminal Sprouting? 
The  maximum  suppression  of terminal  sprouting  achieved 
was obtained with ascites fluid prepared from B 130.6, B 109.9, 
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and B135 (the latter two are IgM's) . Each of the three sup-
pressed sprouting by 50% (Table I) . B109.9 IgM, when puri-
fied from ascites fluid, also suppressed sprouting by 50% (Fig .
8 and Table II). Since none of the mAb suppressed terminal
sprouting completely, we considered two hypotheses. Perhaps
there are two or more signals for sprouting, only one of which
is blocked by the mAb, or perhaps there is only one signal,
but it is blocked incompletely .
To begin to distinguish between the two hypotheses, we
determined a titration curve for the suppression of terminal
sprouting by B 135 . The trend of the relationship between the
amount of B135 injected and the suppression obtained (Fig.
8) suggests that themAb is unlikely to block terminal sprout-
ing completely. A 10-fold increase in the amount of B135
injected-increases the suppression obtained by only twofold .
Although it is not clear that the titration curve has reached a
plateau, despite further increases in the amount of mAb
injected, it appears that the degree of suppression obtained
should be asymptotic with a value between 50 and 60%
suppression .
Lack of complete inhibition might be due to poor pene-
trance of the mAb reagent into the muscle or into the cleft of
the neuromuscular junction ; that remains a possibility, al-
though the two IgM's (B135 and B109.9) suppress terminal
sprouting to the same extent as the IgG2b (B130.6) despite
the substantial differences in their size. The incomplete inhi-
bition obtained may also be simply due to rapid clearance of
the injected mAb from the gluteus muscle such that the
concentration of mAb near the endplates is not as great as
1
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Figure 7 . Two-site RIA with B 130 .6 and B216 . (Left)
[ 358]Methionine-labeled supernatants from B130 .6
and B216 cultures were analyzed by SDS PAGE .
The mAb synthesized by each hybridoma has a
heavy chain of 55 kD which is characteristic of rat
IgG2b (32), yet the size of their light chain differs.
For the two-site RIA (right), microtiter wells were
coated with the indicatedmAb (B130.6 (A] or B216
[" ]) in ascites fluid . The wells were blocked and
then incubated with serial dilutions of the 0.25 M
NaCl DE52 fraction (2° dilution = 10 wg protein/
ml) followed by incubation with 10,000 cpm of
trichloroacetic acid-precipitable [358]-labeled mAb
0
￿
(B130.6* [top] ; B216* [bottom]) . Binding of
B130.6* was observed in wells that had been coated
with B216, but not in those coated with B130 .6 .
Correspondingly, binding ofB216* was observed in
wells coated with B130.6, but not in those coated
with B216. No binding of either [358]-labeled mAb
was observed in the absence of antigen (0) . Thus,
the antigen is monovalent and the two mAb's bind
to distinct epitopes upon the surface of the antigen .
believed . We demonstrated previously thatimmune sera must
be delivered over the surface of the paralyzed muscle; delivery
via the circulation after intraperitoneal injection was not
sufficient to prevent terminal sprouting (16) . That observation
indicates that the concentration ofthe injected antibody must
achieve a sufficient level within the paralyzed muscle in order
for suppression ofterminal sprouting to occur .
Discussion
Results obtained with the anti-56-kD mAb confirm and
extend our previous work with antisera from rabbits immu-
nized with partially purified 56-kD antigen and with the sera
from patients with ALS (16, 17). Suppression of botulinum
toxin-induced motor axon terminal sprouting was obtained
with certain of the anti-56-kD mAb, and furthermore, the
results obtained with the pair of IgG2b, B 130.6 and B216,
indicate that only certain epitopes upon the 56-kD antigen
are functionally important in the gluteus muscle bioassay.
The result again underscores our observation that the sup-
pression ofterminal sprouting that we obtain with the various
immunochemical reagents is highly specific . We previously
demonstrated that polyclonal rabbit antisera directed against
dozens of other antigens present in the denervated muscle-
conditioned medium have no effect on terminal axonal
sprouting; Pestronk and Drachman (30) have similarly shown
that myasthenic sera directed against the acetylcholine recep-
tor do not suppress ultraterminal sprouting in mice . Thus,
the suppression of sprouting that we obtain is unlikely to be100 
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Figure 8.  Titration of anti-56-kD mAb ascites fluid suppression of 
botulinum toxin-induced terminal axonal sprouting. Groups of eight 
mice were injected subcutaneously over the surface of the gluteus 
with botulinum toxin and then received 0.1 ml ofascites fluid (or the 
indicated amount of aseites fluid diluted in 0.1 ml PBS) by subcuta- 
neous injection on each of the next 6 d. B135 ascites fluid contained 
from  I  to 2  mg per milliliter of IgM as estimated by ELISA. The 
mice were killed 7 d after the toxin injection, the gluteus was excised, 
and stained with zinc iodide-osmium tetroxide. The mean and SEM 
of percent terminals sprouting normalized to the percent terminals 
sprouting in  a  group  of toxin-only controls are graphed for each 
group. The dose of toxin used induced 74  +  6% (mean ___  SEM) of 
the gluteal axon terminals to sprout in the toxin-only control. 
Table 11. Suppression of  Motor Axon Terminal Sprouting by 
Purified mAb 
Percent 
mAb  Percent terminals sprouting  inhibition* 
Toxin 3  62 + 4  0 __- 8 
Toxin 4  60 _  8  2 ----- 13 
B86.3 IgG2a  39 -+ 6  36 -  10 
B109.9 IgM  31 __+ 4  49 _  6 
Rat serum lgG2a  56 ___ 5  8 _  9 
B216 ascites  61 ___ 5  0 -  8 
* Calculated from the average of percent terminals sprouting for the toxin 3 
and toxin 4 groups. 
due to nonspecific deposition of immune complexes within 
the synaptic cleft or upon the muscle fiber surface.  Instead, 
the  data argue  that  the  56-kD antigen,  and  indeed,  only a 
limited domain upon the surface of  the protein, is functionally 
important for motor axon terminal sprouting. 
Perturbation of axon terminal sprouting with the anti-56- 
kD mAb does not reveal the biological role of the antigen in 
vivo. Muscle-conditioned medium, our source of the 56-kD 
antigen, has been reported to contain a number of factors that 
are active upon cultured spinal neurons (1, 3,  10,  13, 20, 39). 
Among these are factors that influence neuron attachment to 
and extension of neurites upon the culture substrate,  factors 
that  influence  neuron  survival,  and  a  factor or factors that 
influences  neuronal  expression  of choline  acetyltransferase 
(40). The in vivo experiments do not allow us to identify the 
56-kD antigen with one or another of these biological activi- 
ties. 
Of the soluble,  neuroactive survival factors,  nerve growth 
factor (NGF) remains the best characterized (25,  40).  NGF 
has  both  trophic  and  tropic  activity.  Sympathetic  neurons 
require NGF for growth and survival in culture, and exoge- 
nous NGF can be shown to increase the survival of sympa- 
thetic neurons in vivo (25, 40). Two experiments demonstrate 
the tropic activity of NGF. First, the growing tips of neuritic 
processes  from  sensory  neurons  will  orient  towards  local 
increases  in  NGF concentration  in  vitro  (15),  and  second, 
peripheral  sympathetic afferents will  grow into a  site  of ex- 
ogenous NGF infusion within the brain (28). 
With the realization that only certain populations of neu- 
rons respond to NGF grew the belief that NGF might be only 
one of many neuronal growth factors. Destruction of sympa- 
thetic neurons in vivo with antisera against NGF (the most 
persuasive  demonstration  that  NGF  functions  in  vivo; see 
reference 26) further suggested that target tissues might supply 
trophic factors which specifically maintained their own inner- 
vation.  Thus,  the  death  of spinal  cord motor neurons that 
results from limb bud extirpation (19), and the trophic effects 
of culture  medium  conditioned  by  muscle  for  dissociated 
spinal neurons or spinal cord explants cultured in vitro (1,  3, 
10,  13,  20,  39)  suggested the  existence  of a  muscle-derived 
survival  factor  for  spinal  motor  neurons  (35-38).  Several 
groups have provided evidence that these activities are mod- 
ulated by muscle denervation (21,  29,  37).  Motor axon ter- 
minal  sprouting at  the  neuromuscular junction,  a  local re- 
sponse  to  partial  denervation  in  muscle  (6,  36),  similarly 
seems  to  depend  upon  a  factor derived  from  muscle,  and 
indeed, can be viewed as a tropic action of the hypothesized 
motor  neuron  growth  factor  (7,  35,  38).  Our  preliminary 
results  associate  the  56-kD  antigen  with  a  spinal  neuron 
survival activity assayed in culture (18). 
Most  studies  of ultraterminal  sprouting  in  vivo  indicate 
that the signal for sprouting travels at most a few muscle fiber 
diameters  (2,  6,  36).  Since  the  biological  response  is  the 
outgrowth of new neuritic  processes,  perhaps  factors which 
directly influence neurite extension  in culture assays will  be 
most relevant to the situation  in vivo. Two components of 
the muscle fiber surface or extracellular matrix, N-CAM (for 
neural  cell adhesion  molecule) and laminin  (9,  34),  respec- 
tively, are active on spinal neurons in culture (8, 24, 27, 31). 
No evidence that laminin is regulated by denervation has yet 
been published,  whereas N-CAM shows a  dramatic redistri- 
bution upon the muscle fiber surface after denervation (9).  In 
normal muscle, N-CAM is localized to the endplate region. 
Denervation  or  paralysis  induces  appearance  of  N-CAM 
across  the  muscle  fiber  surface  and  accumulation  within 
interstitial  spaces.  Upon  reinnervation,  extrajunctional  N- 
CAM expression is suppressed. Since F(ab)2 fragments of  anti- 
N-CAM antibody disrupt  adhesion  of neurites  from  spinal 
cord explants to skeletal myotubes in culture (14, 33), mod- 
ulation  of N-CAM expression  may be  highly important  for 
ultraterminal sprouting. The hypothesis should be testable in 
vivo by application of F(ab)2  fragments of anti-mammalian 
N-CAM antibody to a  preparation  such  as the  botulinum- 
intoxicated mouse gluteus muscle. 
Gurney et at. Motor Axon Terminal Sprouting  2271 The present study does not resolve the question of whether 
the 56-kD antigen is a sprouting factor, and therefore,  suffi- 
cient in and of itself to induce terminal axonal sprouting, or 
whether  it  is a  necessary  co-factor  for sprouting.  Complete 
suppression was not achieved with any of the immunochem- 
ical reagents, possibly due to limitations of the in vivo assay, 
such as incomplete penetrance of the mAb into the muscle or 
variable  affinity  of the  mAb.  We  feel  that  the  most  likely 
alternative,  however,  is that there are a  number of require- 
ments  for motor axon terminal  sprouting among which  we 
would  include  the  soluble,  muscle-derived  antigen  that  is 
identified  by  the  monoclonal  antibodies  described  in  this 
report. 
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